Have a personal or library account? Click to login
EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides Cover

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

Radiology and Oncology
Volume 49 (2015): Issue 1 (March 2015)
By: Jörgen Carlsson,  Kenneth Wester,  Manuel De La Torre,  Per-Uno Malmström and  Truls Gårdmark  
Open Access
|Mar 2015

References

  1. 1. Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 2014; 33: 1073-81.10.1038/onc.2013.74387441923542173
    Search in Google Scholar
  2. 2. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; 18: 4986-96.10.1158/1078-0432.CCR-12-0792344570622825581
    Search in Google Scholar
  3. 3. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26: 3637-43.10.1038/sj.onc.121037917530017
    Search in Google Scholar
  4. 4. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007; 75: 788-99.10.1111/j.1432-0436.2007.00200.x17608727
    Search in Google Scholar
  5. 5. Calabrò F, Sternberg CN. Metastatic bladder cancer: anything new? Curr Opin Support Palliat Care 2012; 6: 304-9.
    Search in Google Scholar
  6. 6. Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep 2010; 12: 278-83.
    Search in Google Scholar
  7. 7. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-7210.1158/1078-0432.CCR-08-2245593862419671845
    Search in Google Scholar
  8. 8. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65: 10524-35.10.1158/0008-5472.CAN-05-153616288045
    Search in Google Scholar
  9. 9. Goldenberg DM, and Sharkey RM. Using antibodies to target cancer therapeutics Expert Opin Biol Ther 2012; 12: 1173-90.
    Search in Google Scholar
  10. 10. Thomadsen B, Erwin W, Mourtada F. The physics and radiobiology of targeted radionuclide therapy. In: Speer TW, ed. Targeted radionuclide therapy. Lippincott Williams & Wilkins, Philadelphia; 2011, Chapter 6, p. 71-87. ISBN 978-0-7817-9693-4.
    Search in Google Scholar
  11. 11. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-80.10.1016/j.febslet.2010.04.01420388508
    Search in Google Scholar
  12. 12. Carlsson J, Stigbrand T, Adams GP. Introduction to radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer Verlag. Springer Science+Business Media France; 2008, Chapter 1, p. 1-11. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_1
    Search in Google Scholar
  13. 13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.10.1038/3505207311252954
    Search in Google Scholar
  14. 14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011; 12: 104-17.10.1038/nrm304821252999
    Search in Google Scholar
  15. 15. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-34.10.1016/j.ceb.2007.02.00817314037
    Search in Google Scholar
  16. 16. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.10.1038/nrm196216829981
    Search in Google Scholar
  17. 17. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14: 262-70.10.1016/j.semcancer.2004.04.00515219619
    Search in Google Scholar
  18. 18. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-65.10.1038/sj.onc.120408211426640
    Search in Google Scholar
  19. 19. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-20.10.1080/0300888080228503219054893
    Search in Google Scholar
  20. 20. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.10.1002/ijc.2551621351269
    Search in Google Scholar
  21. 21. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.10.1016/j.ejca.2012.12.02723485231
    Search in Google Scholar
  22. 22. Gardmark T, Wester K, DeLa Torre M, Carlsson J, Malmström PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. Brit J Urol (BJU) 2005; 95: 982-86.10.1111/j.1464-410X.2005.05452.x15839918
    Search in Google Scholar
  23. 23. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41: 282-88.10.1080/0284186026008883612195748
    Search in Google Scholar
  24. 24. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007; 31: 493-9.
    Search in Google Scholar
  25. 25. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003; 16: 173-182.10.1097/01.MP.0000052102.90815.8212591971
    Search in Google Scholar
  26. 26. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011; 60: 350-7.10.1016/j.eururo.2011.05.035
    Search in Google Scholar
  27. 27. Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14: 261-6.10.1007/s12253-008-9027-y
    Search in Google Scholar
  28. 28. Hauser-Kronberger C, Peham K, Grall J, Rausch W, Hutarew G, Dietze O. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol 2006; 175(3 Pt 1): 875-80.10.1016/S0022-5347(05)00411-8
    Search in Google Scholar
  29. 29. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/ neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.
    Search in Google Scholar
  30. 30. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer 2002; 95: 1650-5.10.1002/cncr.1083912365012
    Search in Google Scholar
  31. 31. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 2010; 51: 89-97.10.2967/jnumed.109.07323920484419
    Search in Google Scholar
  32. 32. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14: 2999-3019.10.2174/13816120878640429018991715
    Search in Google Scholar
  33. 33. Heskamp S, van Laarhoven HW, Oyen WJ, van der Graaf WT, Boerman OC. Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. Curr Mol Med 2013; 13: 1506-22.10.2174/156652401366613111112063824206139
    Search in Google Scholar
  34. 34. Fox JJ, Schöder H, Larson SM. Molecular imaging of prostate cancer. Curr Opin Urol 2012; 22: 320-7.10.1097/MOU.0b013e32835483d5437334922617062
    Search in Google Scholar
  35. 35. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.10.1200/JCO.2005.03.844816710024
    Search in Google Scholar
  36. 36. Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 2013; 66: 113-9.10.1136/jclinpath-2012-20094423087329
    Search in Google Scholar
  37. 37. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106: 1216-22.10.1111/j.1464-410X.2009.09190.x20089105
    Search in Google Scholar
  38. 38. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 2010; 10: 407-15.10.4161/cbt.10.5.1302220686360
    Search in Google Scholar
  39. 39. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008; 40: 321-7.10.1007/s11255-007-9283-x17899426
    Search in Google Scholar
  40. 40. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008; 9: 55-61.10.1007/s11934-008-0011-618366975
    Search in Google Scholar
  41. 41. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002; 102: 514-8.10.1002/ijc.1073112432555
    Search in Google Scholar
  42. 42. Jimenez RE, Hussain M, Bianco FJ Jr, Valshampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-7.
    Search in Google Scholar
  43. 43. Carlsson J. Potential for clinical radionuclide based imaging and therapy of common cancers expressing EGFR-family receptors. Tumor Biol 2012; 33: 653-9.10.1007/s13277-011-0307-x22228543
    Search in Google Scholar
  44. 44. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012; 43: 1590-5.10.1016/j.humpath.2011.11.016350567322406363
    Search in Google Scholar
  45. 45. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer Verlag. Springer Science+Business Media France; 2008, Chapter 3, p. 25-58. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_3
    Search in Google Scholar
  46. 46. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol 2010; 37: 265-75. 10.1016/j.nucmedbio.2009.11.00820346866
    Search in Google Scholar
  47. 47 . Tolmachev V, Tran TA, Rosik D, Sjoberg A, Abrahmsen L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012; 53: 953-60. 10.2967/jnumed.111.10152722586147
    Search in Google Scholar
  48. 48 . Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011; 38: 531-39.10.1007/s00259-010-1646-3
    Search in Google Scholar
  49. 49. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 1986; 55: 588-92.
    Search in Google Scholar
  50. 50. Gusterson B, Cowley G, Smith JA, Ozanne B. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 1984; 8: 649-58.10.1016/0309-1651(84)90045-6
    Search in Google Scholar
  51. 51. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ research. J BUON 2009; 14: 457-62.
    Search in Google Scholar
  52. 52. Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol 2011; 27: 208-14.10.4103/0970-1591.82839314283121814311
    Search in Google Scholar
  53. 53. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-61.10.1002/ijc.29104503141968437
    Search in Google Scholar
  54. 54. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-62.
    Search in Google Scholar
  55. 55. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012; 12: 873-90.10.1517/14712598.2012.68515322679911
    Search in Google Scholar
  56. 56. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91.10.1056/NEJMoa1209124512525023020162
    Search in Google Scholar
  57. 57. Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011; 52: 1188-99.10.3109/10428194.2011.57039621599576
    Search in Google Scholar
  58. 58. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26(5 Suppl 14): 58-65.
    Search in Google Scholar
  59. 59. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39(Suppl 1): S103-12.10.1007/s00259-011-2039-y330406522388631
    Search in Google Scholar
  60. 60. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010; 37: 212-25.10.1007/s00259-009-1216-819727718
    Search in Google Scholar
  61. 61. Williams SP. Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging. AAPS J 2012; 14: 389-99.10.1208/s12248-012-9348-3338580922467336
    Search in Google Scholar
  62. 62. Matthews PM, Rabiner EA, Passchier J, Gunn RN. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 2012; 73: 175-86.10.1111/j.1365-2125.2011.04085.x326957621838787
    Search in Google Scholar
  63. 63. Ståhl S, Friedman M, Carlsson J, Tolmachev V, Frejd F. Affibody molecules for targeted radionuclide therapy. In: Speer TW, editor. Targeted radionuclide therapy. Lippincott Williams & Wilkins; 2011. Chapter 4, p. 49-58.
    Search in Google Scholar
  64. 64. Gomes CM, Abrunhosa AJ, Ramos P, Pauwels EK. Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev 2011; 63: 547-54.10.1016/j.addr.2010.09.01520933557
    Search in Google Scholar
  65. 65. Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L. Nuclisome: A novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 2010; 37: 114-23.10.1007/s00259-009-1225-719662408
    Search in Google Scholar
  66. 66. Stigbrand T, Carlsson J, Adams GP. Developmental trends in targeted radionuclide therapy - biological aspects. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer verlag. Springer Science+Business Media France; 2008, Chapter 21, p. 387-97. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_21
    Search in Google Scholar
  67. 67. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 2007; 67: 326-31. 10.1158/0008-5472.CAN-06-236317210714
    Search in Google Scholar
DOI: https://doi.org/10.2478/raon-2014-0015 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 50 - 58
Submitted on: Jan 25, 2014
|
Accepted on: Mar 24, 2014
|
Published on: Mar 3, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
EGFR,
HER2,
radionuclides,
resistance,
urinary bladder cancer metastases
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2015 Jörgen Carlsson, Kenneth Wester, Manuel De La Torre, Per-Uno Malmström, Truls Gårdmark, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 49 (2015): Issue 1 (March 2015)Next article